

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Australian Critical Care 35 (2022) 335

FLSEVIER

Contents lists available at ScienceDirect

Australian Critical Care

journal homepage: www.elsevier.com/locate/aucc

Response

Author's response to "Continuous positive airway pressure helmet in patients with ARDS due to COVID-19 pneumonia: Insights about a therapy monitoring protocol"



AL ACCC

Australian Critical Care

Dear Sir,

Thank you for your interest in our study,¹ and we are grateful for the opportunity to reply to your comments.

We are used to personalising the therapy² by monitoring the respiratory rate (RR) and oxygen saturation and their response to helmet continuous positive airway pressure (H-CPAP) in patients with respiratory failure due to interstitial pneumonia due to COVID-19 because these are the two best independent parameters in noninvasive modality.³ Furthermore, many patients with COVID-19 do not complain of dyspnoea in spite of a marked increase in the RR.⁴ We agree with your reflection: fever and discomfort can change the RR. For this reason, during nursing monitoring, body temperature, SpO₂, RR, PEEP, and FiO₂ were recorded before the H-CPAP trial was started every 30 min until the end of the trial.

We did not analyse the patients' compliance and comfort. These were not endpoints for us. The aim of our case series study was to describe the clinical characteristics of patients presenting to the emergency department with acute respiratory failure due to COVID-19—related pneumonia undergoing treatment with H-CPAP with a strict nursing evaluation and monitoring.

However, during the first 2 h of the H-CPAP trial, we administered morphine in patients who referred to anxiety and discomfort.

We did not analyse the causes of helmet failure as an interface. However, in studies comparing the effectiveness of facemasks, skin lesions are the main complications of noninvasive ventilation delivered,⁵ whereas with helmet, this problem could be avoided since there is no direct contact between the helmet and the patient's face. On the other hand, noise needs to be reduced to increase patients' comfort and tolerance to the respiratory support.⁶ We suggest that the percent of interface failure in our study is comparable to the one in the previous studies.⁷

As regard your last question, according to the literature,⁸ all our patients were prophylaxed with low-molecular-weight heparin.

CRediT authorship contribution statement

Daniele Privitera, Nicolò Capsoni, Andrea Bellone: Conceptualisation, Visualisation, Supervision, Writing-Reviewing and Editing.

References

- [1] Privitera D, Capsoni N, Mazzone A, Airoldi C, Angaroni L, Pierotti F, et al. Nursing evaluation during treatment with helmet continuous positive airway pressure in patients with respiratory failure due to COVID-19 pneumonia: a case series. Aust Crit Care 2022;35(1):46–51. https://doi.org/10.1016/j.aucc.2021.10.001.
- [2] Privitera D, Angaroni L, Capsoni N, Forni E, Pierotti F, Vincenti F, et al. Flowchart for non-invasive ventilation support in COVID-19 patients from a northern Italy Emergency Department. Intern Emerg Med 2020;15(5):767-71. https://doi.org/ 10.1007/s11739-020-02370-8.
- [3] Brambilla AM, Aliberti S, Prina E, Nicoli F, Del Forno M, Nava S, et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia [published correction appears in Intensive Care Med. 2014 Aug;40(8): 1187] Intensive Care Med 2014;40(7):942–9. https://doi.org/10.1007/s00134-014-3325-5.
- [4] Di Domenico SL, Coen D, Bergamaschi M, Albertini V, Ghezzi L, Cazzaniga MM, et al. Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-center retrospective study. Intern Emerg Med 2021;16(4):1051–60. https://doi.org/10.1007/s11739-020-02548-0.
- [5] Pisani L, Carlucci A, Nava S. Interfaces for noninvasive mechanical ventilation: technical aspects and efficiency. Minerva Anestesiol 2012;78(10):1154–61.
- [6] Cavaliere F, Conti G, Costa R, Proietti R, Sciuto A, Masieri S. Noise exposure during noninvasive ventilation with a helmet, a nasal mask, and a facial mask. Intensive Care Med 2004;30(9):1755–60.
- [7] Aliberti S, Radovanovic D, Billi F, Sotgiu G, Costanzo M, Pilocane T, et al. Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study. Eur Respir J 2020 Oct 15;56(4):2001935. https://doi.org/10.1183/ 13993003.01935-2020.
- [8] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094–9.

Daniele Privitera, MSN, CCRN^{*}, Nicolò Capsoni, MD, Andrea Bellone, MD Department of Emergency Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

* Corresponding author. Tel +390264442294. E-mail address: daniele.privitera@ospedaleniguarda.it (D. Privitera).

16 March 2022

https://doi.org/10.1016/j.aucc.2022.03.008

1036-7314/© 2022 Australian College of Critical Care Nurses Ltd. Published by Elsevier Ltd. All rights reserved.

DOI of original article: https://doi.org/10.1016/j.aucc.2022.03.006.